Clinical trial · Interventional
SU6668 in Treating Patients With Advanced Solid Tumors
A Phase I Surrogate Endpoint Trial of SU6668 in Patients With Incurable Solid Tumors
NCT00024206CI-TRIAL-00009045completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase I trial to study the effectiveness of SU6668 in treating patients who have advanced solid tumors. SU6668 may stop the growth of solid tumors by stopping blood flow to the tumor
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| orantinib | Drug | — | UNRESOLVED |
| pharmacological study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (orantinib)
- description
- Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more. Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- interventionNames
- Drug: orantinib
- Other: laboratory biomarker analysis
- Other: pharmacological study
Primary outcomes (2)
- measure
- Incidence of adverse events, as defined by the Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) term and body system, graded according to the National Cancer Institute Common Toxicity Criteria v2.0
- timeFrame
- Up to 2 years
- measure
- Maximally tolerated dose of orantinib, graded according to the NCI CTC v2.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed advanced solid tumor for which no standard therapy exists * At least 1 measurable tumor lesion (at least 2 cm) not previously irradiated * No history of brain metastases * Negative brain CT/MRI required for patients with signs and symptoms suspicious for brain metastases * Performance status - ECOG 0-1 * WBC greater than 3,000/mm\^3 * Absolute neutrophil count greater than 1,500/mm\^3 * Platelet count greater than 100,000/mm\^3 * Hemoglobin greater than 10 g/dL * No history of bleeding diathesis * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * ALT less than 2.5 times ULN * Creatinine less than 1.5 mg/dL * Creatinine clearance greater than 60 mL/min * No concurrent uncontrolled medical or psychiatric disorders * No severe iodine allergy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * At least 30 days since prior over-the-counter, anticancer biologic agents (e.g., shark cartilage) * No concurrent over-the-counter, anticancer biologic agents (e.g., shark cartilage) * At least 3 weeks since prior cytotoxic or cytostatic agents (6 weeks for nitrosoureas or mitomycin) * Patients with ECOG performance status 0: * Any number of prior chemotherapy regimens allowed * Patients with ECOG performance status 1: * No more than 3 prior chemotherapy regimens for metastatic or recurrent disease * The same drug given on a different schedule does not count as a different regimen * Prior adjuvant chemotherapy for non-metastatic disease or as part of a concurrent chemoradiotherapy protocol is allowed but does not count as part of the 3-regimen limit * See Disease Characteristics * See Chemotherapy * At least 3 weeks since prior radiotherapy to nonindicator lesions * No concurrent radiotherapy * At least 24 hours since prior minor surgery (e.g., central venous catheter placement) * At least 4 weeks since prior major surgery (e.g., laparotomy, thoracotomy, or craniotomy) * At least 30 days since prior anticancer herbal remedies * At least 30 days since prior investigational agents * No concurrent anticancer herbal remedies * No other concurrent investigational or anticancer medication
References
Publications (0)
Data not yet available
No reference posted for this study.